US2019360061A1PendingUtilityA1

Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer

48
Assignee: BIO MARCARE TECH LTDPriority: Apr 10, 2014Filed: Aug 13, 2019Published: Nov 28, 2019
Est. expiryApr 10, 2034(~7.7 yrs left)· nominal 20-yr term from priority
Inventors:Dana CohenVardit MoshayoffOuriel Faktor
C12Q 1/6886C12Q 2600/158C12Q 2600/112A61K 31/513A61K 31/519A61K 31/555A61K 31/7068C12Q 2600/118
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and kits for identifying a subject having pre-cancerous advanced polyps or colorectal cancer based on the expression profile(s) of specific mRNA biomarkers. Methods and kits for diagnosing, preventing, managing therapy, monitoring and identifying predisposition to colorectal cancer.

Claims

exact text as granted — not AI-modified
1 . A method for treating colorectal cancer or precancerous advanced colorectal polyps in a subject, the method comprising:
 (a) obtaining sample mRNA from the subject;   (b) detecting overexpression of a biomarker comprising at least one nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-17; and   (c) treating the subject with overexpression of the at least one nucleic acid sequence, wherein the treatment comprises at least one of administering a chemotherapeutic agent, performing bowel resection, applying radiation therapy, and a combination thereof.   
     
     
         2 . The method of  claim 1 , wherein said biomarker comprises a plurality of nucleic acid sequences selected from the group consisting of SEQ ID NO: 1-17. 
     
     
         3 . The method of  claim 2 , wherein said biomarker comprises at least three nucleic acid sequences selected from the group consisting of SEQ ID NO: 1-17. 
     
     
         4 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 1 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 2-17. 
     
     
         5 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 2 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 and 3-17. 
     
     
         6 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 3 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, 2 and 4-17. 
     
     
         7 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 4 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-3 and 5-17. 
     
     
         8 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 5 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-4 and 6-17. 
     
     
         9 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 6 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-5 and 7-17. 
     
     
         10 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 7 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-6 and 8-17. 
     
     
         11 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 8 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-7 and 9-17. 
     
     
         12 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 9 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-8 and 10-17. 
     
     
         13 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 10 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-9 and 11-17. 
     
     
         14 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 11 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-10 and 12-17. 
     
     
         15 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 12 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-11 and 13-17. 
     
     
         16 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 13 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-12 and 14-17. 
     
     
         17 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 14 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-13 and 15-17. 
     
     
         18 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 15 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-14 and 16-17. 
     
     
         19 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 16 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-15 and 17. 
     
     
         20 . The method of  claim 1 , wherein said biomarker comprises SEQ ID NO: 17 and at least one additional nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-16.

Join the waitlist — get patent alerts

Track US2019360061A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.